PMID- 34585933
OWN - NLM
STAT- MEDLINE
DCOM- 20220221
LR  - 20220221
IS  - 1543-8392 (Electronic)
IS  - 1543-8384 (Linking)
VI  - 18
IP  - 11
DP  - 2021 Nov 1
TI  - Recent Progress in Polymeric AIE-Active Drug Delivery Systems: Design and 
      Application.
PG  - 3951-3965
LID - 10.1021/acs.molpharmaceut.1c00601 [doi]
AB  - Aggregation-induced emission (AIE) provides a new opportunity to overcome the 
      drawbacks of traditional aggregation-induced quenching of chromophores. The 
      applications of AIE-active fluorophores have spread across various fields. In 
      particular, the employment of AIEgens in drug delivery systems (DDSs) can achieve 
      imaging-guided therapy and pharmacodynamic monitoring. As a result, polymeric 
      AIE-active DDSs are attracting increasing attention due to their obvious 
      advantages, including easy fabrication and tunable optical properties by 
      molecular design. Additionally, the design of polymeric AIE-active DDSs is a 
      promising method for cancer therapy, antibacterial treatment, and pharmacodynamic 
      monitoring, which indeed helps improve the effectiveness of related disease 
      treatments and confirms its potential social importance. Here, we summarize the 
      current available polymeric AIE-active DDSs from design to applications. In the 
      design section, we introduce synthetic strategies and structures of AIE-active 
      polymers, as well as responsive strategies for specific drug delivery. In the 
      application section, typical polymeric AIE-active DDSs used for cancer therapy, 
      bacterial treatment, and drug delivery monitoring are summarized with selected 
      examples to elaborate on their wide applications.
FAU - Pei, Yang
AU  - Pei Y
AD  - School of History, Nanjing University, Nanjing, Jiangsu 210023, People's Republic 
      of China.
FAU - Wang, Ziyu
AU  - Wang Z
AD  - State Key Laboratory of Radiation Medicine and Protection, School for 
      Radiological and Interdisciplinary Sciences (RAD-X), Soochow University, Suzhou, 
      Jiangsu 215123, People's Republic of China.
FAU - Wang, Cheng
AU  - Wang C
AUID- ORCID: 0000-0001-5087-3027
AD  - The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, 
      Changzhou, Jiangsu 213000, People's Republic of China.
AD  - School of Pharmacy, Changzhou University, Changzhou, Jiangsu 213164, People's 
      Republic of China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210929
PL  - United States
TA  - Mol Pharm
JT  - Molecular pharmaceutics
JID - 101197791
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Polymers)
SB  - IM
MH  - Anti-Bacterial Agents/*administration & dosage
MH  - Antineoplastic Agents/*administration & dosage
MH  - Bacterial Infections/drug therapy
MH  - Drug Delivery Systems/*methods
MH  - Drug Monitoring/methods
MH  - Fluorescence
MH  - Humans
MH  - Neoplasms/drug therapy
MH  - Polymers/*chemistry
OTO - NOTNLM
OT  - AIE-active polymer
OT  - aggregation-induced emission
OT  - bacterial treatment
OT  - cancer therapy
OT  - drug delivery monitoring
OT  - drug delivery system
OT  - peacebuilding
EDAT- 2021/09/30 06:00
MHDA- 2022/02/22 06:00
CRDT- 2021/09/29 12:14
PHST- 2021/09/30 06:00 [pubmed]
PHST- 2022/02/22 06:00 [medline]
PHST- 2021/09/29 12:14 [entrez]
AID - 10.1021/acs.molpharmaceut.1c00601 [doi]
PST - ppublish
SO  - Mol Pharm. 2021 Nov 1;18(11):3951-3965. doi: 10.1021/acs.molpharmaceut.1c00601. 
      Epub 2021 Sep 29.